Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts. Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak płaskonabłonkowy przełyku, który jest zaawansowany i nie można go usunąć operacyjnie, lub który rozprzestrzenił się na inne części ciała, i jest to pierwszy etap leczenia.
- •Rak przełyku, który można zmierzyć za pomocą badań obrazowych.
- •Dolegliwości uboczne po wcześniejszym leczeniu raka ustąpiły lub są łagodne.
- •Osoby zakażone wirusem HIV muszą mieć dobrze kontrolowane wirusy dzięki leczeniu.
- •Ogólny stan zdrowia pozwala na aktywność (skala 0-1).
- •Narządy wewnętrzne działają prawidłowo.
✗ Disqualifies
- •Osoby, które już przyjmowały inne leki przeciwnowotworowe w leczeniu tego rodzaju raka przełyku.
- •Rak naciekający na sąsiednie narządy, co zwiększa ryzyko powstania przetoki.
- •Płyn w jamie opłucnej, osierdziu lub brzuchu, który wymaga częstego odprowadzania.
- •Ciężkie choroby oczu lub suchość oka, które mogą utrudniać gojenie się rogówki.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (43)
UPMC Hillman Cancer Center ( Site 1904)
Pittsburgh, United States
Liga Norte Riograndense Contra o Cancer ( Site 1301)
Natal, Brazil
Hospital Nossa Senhora da Conceicao ( Site 1300)
Porto Alegre, Brazil
Clínica Puerto Montt ( Site 1406)
Port Montt, Chile
FALP ( Site 1400)
Santiago, Chile
Centro de Oncología de Precisión ( Site 1402)
Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 1403)
Santiago, Chile
Bradfordhill ( Site 1401)
Santiago, Chile
Bradford Hill Norte ( Site 1405)
Antofagasta, Chile
The Second Affiliated Hospital of Anhui Medical University ( Site 9511)
Hefei, China
Beijing Cancer Hospital ( Site 9500)
Beijing, China
The First Affiliated Hospital of Xiamen University ( Site 9503)
Xiamen, China
Henan Cancer Hospital ( Site 9509)
Zhengzhou, China
Xuzhou Central Hospital ( Site 9512)
Xuzhou, China
The First Affiliated Hospital of Nanchang University ( Site 9505)
Nanchang, China
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 9000)
Brno, Czechia
C.H.R.U. de Brest - Hopital Cavale Blanche ( Site 9104)
Brest, France
CHU Lille - Institut Coeur Poumon ( Site 9100)
Lille, France
Pitie Salpetriere University Hospital ( Site 9102)
Paris, France
Universitaetsklinikum Duesseldorf ( Site 1808)
Düsseldorf, Germany
Universitätsklinikum Carl Gustav Carus - Medical Oncology ( Site 1806)
Dresden, Germany
Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 1807)
Hamburg, Germany
Ospedale San Raffaele-Oncologia Medica ( Site 9201)
Milan, Italy
Istituto Oncologico Veneto IRCCS ( Site 9202)
Padova, Italy
Aichi Cancer Center ( Site 9702)
Nagoya, Japan
National Cancer Center Hospital East ( Site 9701)
Kashiwa, Japan
National Cancer Center Hospital ( Site 9700)
Chūō, Japan
Oslo Universitetssykehus Radiumhospitalet ( Site 1501)
Oslo, Norway
National University Hospital ( Site 9800)
Singapore, Singapore
National Cancer Center ( Site 9902)
Goyang-si, South Korea
Asan Medical Center ( Site 9901)
Seoul, South Korea
Samsung Medical Center ( Site 9900)
Seoul, South Korea
Kantonsspital Graubuenden ( Site 1700)
Chur, Switzerland
Hopitaux Universitaires de Geneve HUG. ( Site 1701)
Geneva, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1009)
Kaoshiung, Taiwan
Kaohsiung Chang Gung Memorial Hospital ( Site 1003)
Kaohsiung City, Taiwan
China Medical University Hospital ( Site 1007)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 1001)
Tainan, Taiwan
National Taiwan University Hospital ( Site 1000)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 1005)
Taipei, Taiwan
Chang Gung Memorial Hospital - Linkou Branch ( Site 1006)
Taoyuan, Taiwan
Ramathibodi Hospital ( Site 1103)
Ratchathewi, Thailand
Songklanagarind hospital ( Site 1101)
Hat Yai, Thailand
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.